PE20110075A1 - Sintesis de compuestos de ester borico - Google Patents
Sintesis de compuestos de ester boricoInfo
- Publication number
- PE20110075A1 PE20110075A1 PE2009001314A PE2009001314A PE20110075A1 PE 20110075 A1 PE20110075 A1 PE 20110075A1 PE 2009001314 A PE2009001314 A PE 2009001314A PE 2009001314 A PE2009001314 A PE 2009001314A PE 20110075 A1 PE20110075 A1 PE 20110075A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- aliphatic
- ether
- terc
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000011541 reaction mixture Substances 0.000 abstract 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 abstract 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 abstract 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 abstract 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 abstract 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 abstract 1
- 239000002841 Lewis acid Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 229910052796 boron Inorganic materials 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 abstract 1
- 150000007517 lewis acids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229940102001 zinc bromide Drugs 0.000 abstract 1
- 235000005074 zinc chloride Nutrition 0.000 abstract 1
- 239000011592 zinc chloride Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
SE REFIERE A UN PROCESO DE PREPARACION DE UN COMPUESTO DE ESTER BORICO DE FORMULA (I) DONDE R1 ES UN GRUPO ALIFATICO C1-C8, ARILO C6-C10 O (ARILO C6-C10)-(ALIFATICO C1-C6); R2 ES H, HALOGENO; R3 ES HALOGENO; R4 Y R5 SON CA UNO ALIFATICO C1-C12, AROMATICO C6-C14, HETEOAROMATICO DE 5 A 14 MIEMBROS CON 1-4 HETEROATOMOS SELECCIONADOS DE O, N, S. DICHO PROCESO COMPRENDE LAS ETAPAS DE: A) PROPORCIONAR UN COMPLEJO BORON"ATO" DE FORMULA (II) DONDE Y ES HALOGENO, M+ ES Li+, Na+, K+; R1 A R5 ES COMO SE HA DEFINIDO ANTERIORMENTE; B) PONER EN CONTACTO EL COMPLEJO CON UN ACIDO LEWIS TALES COMO CLORURO DE ZINC, CLORURO FERRICO, BROMURO DE ZINC, ENTRE OTROS. DICHA ETAPA SE REALIZA MEDIANTE UNA MEZCLA QUE COMPRENDE UN DISOLVENTE ETER SELECCIONADO DE TERC-BUTIL METIL ETER, TERC-BUTIL ETIL ETER, ISOPROPIL ETER, ENTRE OTROS Y UN COSOLVENTE DE COORDINACION SELECCIONADO DE DIOXANO, AGUA, DIOXANO, TETRAHIDROFURANO Y MEZCLAS DE LOS MISMOS; C) LAVAR LA MEZCLA DE REACCION CON UNA SOLUCION ACUOSA; D) CONCENTRAR LA MEZCLA DE REACCION
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55753504P | 2004-03-30 | 2004-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20110075A1 true PE20110075A1 (es) | 2011-02-17 |
Family
ID=34968044
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014001477A PE20142402A1 (es) | 2004-03-30 | 2005-03-29 | Sintesis de compuestos de ester y acido borico |
PE2009001314A PE20110075A1 (es) | 2004-03-30 | 2005-03-29 | Sintesis de compuestos de ester borico |
PE2005000359A PE20060162A1 (es) | 2004-03-30 | 2005-03-29 | Sintesis de compuestos de ester y acido borico |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014001477A PE20142402A1 (es) | 2004-03-30 | 2005-03-29 | Sintesis de compuestos de ester y acido borico |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005000359A PE20060162A1 (es) | 2004-03-30 | 2005-03-29 | Sintesis de compuestos de ester y acido borico |
Country Status (41)
Country | Link |
---|---|
US (14) | US7714159B2 (es) |
EP (5) | EP1756121B1 (es) |
JP (4) | JP4558039B2 (es) |
KR (1) | KR100939598B1 (es) |
CN (5) | CN1960996B (es) |
AR (3) | AR049374A1 (es) |
AT (1) | ATE521612T1 (es) |
AU (1) | AU2005230930B2 (es) |
BR (1) | BRPI0509587A (es) |
CA (4) | CA2738706C (es) |
CL (2) | CL2010000350A1 (es) |
CR (1) | CR8653A (es) |
CY (3) | CY1112053T1 (es) |
DK (4) | DK3385267T3 (es) |
DO (1) | DOP2011000293A (es) |
EA (1) | EA012927B1 (es) |
EC (1) | ECSP066960A (es) |
ES (3) | ES2899606T3 (es) |
FI (1) | FI4008721T3 (es) |
HK (4) | HK1100004A1 (es) |
HR (4) | HRP20212002T1 (es) |
HU (1) | HUE056859T2 (es) |
IL (3) | IL178250A (es) |
LT (2) | LT3385267T (es) |
ME (1) | ME01975B (es) |
MX (1) | MX367324B (es) |
MY (1) | MY145427A (es) |
NL (3) | NL1028639C2 (es) |
NO (4) | NO338905B1 (es) |
NZ (3) | NZ586824A (es) |
PE (3) | PE20142402A1 (es) |
PL (4) | PL2377869T3 (es) |
PT (4) | PT1756121E (es) |
RS (4) | RS51983B (es) |
SG (5) | SG10201800972PA (es) |
SI (4) | SI1756121T1 (es) |
TW (1) | TWI386212B (es) |
UA (1) | UA90108C2 (es) |
UY (3) | UY28830A1 (es) |
WO (1) | WO2005097809A2 (es) |
ZA (1) | ZA200608689B (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
CA2738706C (en) | 2004-03-30 | 2014-10-14 | Millennium Pharmaceuticals, Inc. | Synthesis of boronic ester and acid compounds |
WO2008075376A1 (en) * | 2006-12-18 | 2008-06-26 | Natco Pharma Limited | Polymorphic forms of bortezomib and process for their preparation |
WO2009004350A1 (en) * | 2007-07-03 | 2009-01-08 | Pliva Hrvatska D.O.O. | Methods for preparing bortezomib and intermediates used in its manufacture |
EA034601B1 (ru) * | 2007-08-06 | 2020-02-25 | Милленниум Фармасьютикалз, Инк. | Способ получения бороновых кислот |
EP2527347A1 (en) * | 2007-08-06 | 2012-11-28 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
AU2016253697A1 (en) * | 2007-08-06 | 2016-11-24 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
US20110118274A1 (en) * | 2007-08-23 | 2011-05-19 | Cornell Research Foundation, Inc. | Proteasome inhibitors and their use in treating pathogen infection and cancer |
AU2008298694A1 (en) * | 2007-09-12 | 2009-03-19 | Dr. Reddy's Laboratories Ltd. | Bortezomib and process for producing same |
US7838673B2 (en) | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
EP2730580A1 (en) * | 2008-06-17 | 2014-05-14 | Millennium Pharmaceuticals, Inc. | Boronate ester compounds and pharmaceutical compositions thereof |
AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
AU2013204881A1 (en) * | 2008-09-29 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclobutylethylboronic acid |
EP2238973A1 (en) | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilized preparations of proteasome inhibitors |
CN101899062B (zh) * | 2009-05-26 | 2015-04-15 | 上海威智医药科技有限公司 | α-手性硼酸及硼酸酯的合成工艺 |
CN102803271B (zh) * | 2009-06-19 | 2016-03-23 | 力奇制药公司 | 氢化卤代烯烃而不脱卤的方法 |
EP2270019A1 (en) | 2009-06-19 | 2011-01-05 | LEK Pharmaceuticals d.d. | New synthetic route for the preparation of alpha-amino boronic esters |
EP2280016A1 (en) | 2009-07-27 | 2011-02-02 | LEK Pharmaceuticals d.d. | New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes |
WO2011087822A1 (en) | 2009-12-22 | 2011-07-21 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
EP2534159A1 (en) | 2010-02-09 | 2012-12-19 | Ranbaxy Laboratories Limited | Process for the preparation of bortezomib |
CN101781326B (zh) * | 2010-02-11 | 2013-08-21 | 福建南方制药股份有限公司 | 一种制备手性氨基硼酸的中间体及其制备方法 |
WO2011107912A1 (en) | 2010-03-04 | 2011-09-09 | Ranbaxy Laboratories Limited | Polymorphic forms of bortezomib |
US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
WO2011116286A2 (en) * | 2010-03-18 | 2011-09-22 | Innopharma, Llc | Stable bortezomib formulations |
EP2552216B1 (en) | 2010-03-31 | 2018-01-24 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
CN101812026B (zh) * | 2010-04-12 | 2013-08-28 | 亚邦医药股份有限公司 | 一种硼替佐米的合成方法 |
EP2571525A4 (en) | 2010-05-18 | 2016-04-27 | Cerulean Pharma Inc | Compositions and methods for treating autoimmune and other diseases |
ES2548256T3 (es) | 2010-10-14 | 2015-10-15 | Synthon Bv | Proceso para la preparación de bortezomib y los intermedios para el proceso |
TW201309303A (zh) | 2011-03-03 | 2013-03-01 | Cephalon Inc | 用於治療狼瘡的蛋白酶體抑制劑 |
CN102206188B (zh) * | 2011-04-08 | 2013-02-27 | 苏州二叶制药有限公司 | N-(吡嗪-2-基羰基)-l-苯丙氨酸的制备方法 |
US8497374B2 (en) | 2011-05-12 | 2013-07-30 | Scinopharm Taiwan, Ltd. | Process for preparing and purifying bortezomib |
CN102268029B (zh) * | 2011-05-19 | 2013-10-09 | 苏州二叶制药有限公司 | 化合物(1s,2s,3r,5s)-蒎烷二醇-l-苯丙氨酸-l-亮氨酸硼酸酯的制备 |
MX2013015308A (es) | 2011-06-22 | 2014-05-20 | Cephalon Inc | Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso. |
CN102351890B (zh) * | 2011-09-30 | 2014-07-02 | 重庆泰濠制药有限公司 | 一种硼替佐米的合成方法 |
CN102492021B (zh) * | 2011-12-13 | 2013-10-23 | 重庆泰濠制药有限公司 | 硼替佐米的制备工艺 |
JP6129203B2 (ja) | 2011-12-22 | 2017-05-17 | アレス トレーディング ソシエテ アノニム | α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤 |
CN103374026A (zh) * | 2012-04-27 | 2013-10-30 | 重庆医药工业研究院有限责任公司 | 一种硼替佐米中间体的制备方法 |
CN103450331B (zh) * | 2012-06-05 | 2016-05-25 | 山东新时代药业有限公司 | 一种硼替佐米的精制方法 |
WO2014041324A1 (en) * | 2012-09-11 | 2014-03-20 | Cipla Limited | Process for preparing of bortezamib |
WO2014072985A1 (en) | 2012-11-06 | 2014-05-15 | Natco Pharma Limited | Novel boronic acid derivatives as anti cancer agents |
WO2014076713A2 (en) | 2012-11-16 | 2014-05-22 | Shilpa Medicare Limited | Crystalline bortezomib process |
PT2928898T (pt) | 2012-12-07 | 2021-07-05 | Venatorx Pharmaceuticals Inc | Inibidores de beta-lactamase |
CN103897027A (zh) * | 2012-12-29 | 2014-07-02 | 曹亚英 | 关键中间体晶型,制备方法及其在硼替佐米合成中的运用 |
CN103897026A (zh) * | 2012-12-29 | 2014-07-02 | 朱继东 | 硼替佐米关键中间体的晶型,制备方法及其运用 |
US9403850B2 (en) | 2013-01-10 | 2016-08-02 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
CA2909519A1 (en) | 2013-04-16 | 2014-10-23 | Cipla Limited | Process for the preparation of bortezomib mannitol ester |
CN104211758B (zh) * | 2013-05-29 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种硼替佐米的制备方法 |
CN103497233B (zh) * | 2013-09-30 | 2015-04-08 | 哈药集团技术中心 | 一种硼替佐米的制备方法 |
CN103554219A (zh) * | 2013-10-01 | 2014-02-05 | 昆明贵研药业有限公司 | 一种制备硼替佐米的方法 |
KR101691353B1 (ko) * | 2013-12-09 | 2016-12-30 | 주식회사 경보제약 | 보르테조밉의 제조방법 및 그의 신규 중간체 |
US10167311B2 (en) | 2014-02-03 | 2019-01-01 | Ohio State Innovation Foundation | Boronic acid esters and pharmaceutical formulations thereof |
EP3145526A1 (en) | 2014-05-20 | 2017-03-29 | Millennium Pharmaceuticals, Inc. | Boron-containing proteasome inhibitors for use after primary cancer therapy |
CN109988186A (zh) | 2014-06-11 | 2019-07-09 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
JP6420629B2 (ja) * | 2014-10-30 | 2018-11-07 | ボーグワーナー インコーポレーテッド | チェーンガイドおよびチェーンテンショナアーム |
DE102015204151A1 (de) * | 2015-03-09 | 2016-09-15 | Adidas Ag | Ball, insbesondere Fußball, und Verfahren zur Herstellung eines Balls |
JP6223508B2 (ja) * | 2016-06-27 | 2017-11-01 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | プロテアソーム阻害剤 |
EP3494121B1 (en) | 2016-08-04 | 2021-10-06 | Venatorx Pharmaceuticals, Inc. | Boron-containing compounds |
KR20190127681A (ko) | 2017-02-17 | 2019-11-13 | 프레세니어스 카비 온콜로지 리미티드 | 붕소산 에스테르의 개선된 제조방법 |
SG11201908181XA (en) | 2017-03-06 | 2019-10-30 | Venatorx Pharmaceuticals Inc | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
WO2018218154A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
WO2018218190A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
WO2019020099A1 (zh) | 2017-07-28 | 2019-01-31 | 成都地奥九泓制药厂 | 一种硼酸酯化合物、其合成方法及其用途 |
MX2020002187A (es) | 2017-09-02 | 2020-09-22 | Sun Pharmaceutical Ind Ltd | Proceso para la preparacion de citrato de ixazomib. |
CN111187336B (zh) * | 2018-11-14 | 2022-05-20 | 正大天晴药业集团股份有限公司 | 硼替佐米的精制方法 |
US11964993B2 (en) | 2021-07-03 | 2024-04-23 | Shilpa Pharma Lifesciences Limited | Crystalline bortezomib process |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4525309A (en) | 1983-03-15 | 1985-06-25 | Washington State University Research Foundation, Inc. | Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents |
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
US4537773A (en) | 1983-12-05 | 1985-08-27 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid derivatives |
US4701545A (en) | 1986-02-12 | 1987-10-20 | Washington State University Research Foundation, Inc. | Preparation of α,α-dihaloalkyl boronic esters |
US5242904A (en) | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5250720A (en) | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
EP0315574A3 (de) | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
CA2435146C (en) * | 2001-01-25 | 2011-03-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
WO2003033506A1 (fr) * | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant |
JPWO2003033507A1 (ja) | 2001-10-12 | 2005-02-03 | 杏林製薬株式会社 | ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬 |
CA2738706C (en) | 2004-03-30 | 2014-10-14 | Millennium Pharmaceuticals, Inc. | Synthesis of boronic ester and acid compounds |
WO2009004350A1 (en) * | 2007-07-03 | 2009-01-08 | Pliva Hrvatska D.O.O. | Methods for preparing bortezomib and intermediates used in its manufacture |
US7838673B2 (en) * | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
CN102803271B (zh) * | 2009-06-19 | 2016-03-23 | 力奇制药公司 | 氢化卤代烯烃而不脱卤的方法 |
-
2005
- 2005-03-24 CA CA2738706A patent/CA2738706C/en active Active
- 2005-03-24 PT PT05742865T patent/PT1756121E/pt unknown
- 2005-03-24 SG SG10201800972PA patent/SG10201800972PA/en unknown
- 2005-03-24 WO PCT/US2005/009774 patent/WO2005097809A2/en active Application Filing
- 2005-03-24 RS RS20110502A patent/RS51983B/en unknown
- 2005-03-24 PL PL11167264T patent/PL2377869T3/pl unknown
- 2005-03-24 DK DK18172486.5T patent/DK3385267T3/da active
- 2005-03-24 EP EP05742865A patent/EP1756121B1/en active Active
- 2005-03-24 CA CA2859119A patent/CA2859119A1/en not_active Abandoned
- 2005-03-24 HR HRP20212002TT patent/HRP20212002T1/hr unknown
- 2005-03-24 MY MYPI20051304A patent/MY145427A/en unknown
- 2005-03-24 EA EA200601795A patent/EA012927B1/ru unknown
- 2005-03-24 AU AU2005230930A patent/AU2005230930B2/en active Active
- 2005-03-24 PT PT111672648T patent/PT2377869E/pt unknown
- 2005-03-24 EP EP21197526.3A patent/EP4008721B1/en active Active
- 2005-03-24 SG SG2012049755A patent/SG182998A1/en unknown
- 2005-03-24 CN CN200580017645.5A patent/CN1960996B/zh active Active
- 2005-03-24 PL PL18172486T patent/PL3385267T3/pl unknown
- 2005-03-24 HU HUE18172486A patent/HUE056859T2/hu unknown
- 2005-03-24 ES ES18172486T patent/ES2899606T3/es active Active
- 2005-03-24 PT PT181724865T patent/PT3385267T/pt unknown
- 2005-03-24 SI SI200531401T patent/SI1756121T1/sl unknown
- 2005-03-24 ME MEP-2011-502A patent/ME01975B/me unknown
- 2005-03-24 EP EP11167264.8A patent/EP2377869B1/en active Active
- 2005-03-24 PT PT211975263T patent/PT4008721T/pt unknown
- 2005-03-24 AT AT05742865T patent/ATE521612T1/de active
- 2005-03-24 RS RS20240260A patent/RS65253B1/sr unknown
- 2005-03-24 SI SI200532318T patent/SI4008721T1/sl unknown
- 2005-03-24 LT LTEP18172486.5T patent/LT3385267T/lt unknown
- 2005-03-24 LT LTEP21197526.3T patent/LT4008721T/lt unknown
- 2005-03-24 DK DK05742865.8T patent/DK1756121T3/da active
- 2005-03-24 ES ES11167264.8T patent/ES2457593T3/es active Active
- 2005-03-24 CN CN201710810795.6A patent/CN107474062A/zh active Pending
- 2005-03-24 BR BRPI0509587-5A patent/BRPI0509587A/pt not_active Application Discontinuation
- 2005-03-24 PL PL21197526.3T patent/PL4008721T3/pl unknown
- 2005-03-24 CN CN202010514035.2A patent/CN111925385B/zh active Active
- 2005-03-24 DK DK21197526.3T patent/DK4008721T3/da active
- 2005-03-24 RS RS20211565A patent/RS62738B1/sr unknown
- 2005-03-24 KR KR1020067022780A patent/KR100939598B1/ko active IP Right Grant
- 2005-03-24 PL PL05742865T patent/PL1756121T3/pl unknown
- 2005-03-24 SG SG10201600029PA patent/SG10201600029PA/en unknown
- 2005-03-24 EP EP18172486.5A patent/EP3385267B1/en active Active
- 2005-03-24 DK DK11167264.8T patent/DK2377869T3/da active
- 2005-03-24 HR HRP20240307TT patent/HRP20240307T3/hr unknown
- 2005-03-24 JP JP2007506261A patent/JP4558039B2/ja active Active
- 2005-03-24 SG SG2012049763A patent/SG182999A1/en unknown
- 2005-03-24 CA CA2560886A patent/CA2560886C/en active Active
- 2005-03-24 CA CA2853272A patent/CA2853272A1/en not_active Abandoned
- 2005-03-24 CN CN201310294873.3A patent/CN103396427B/zh active Active
- 2005-03-24 UA UAA200611339A patent/UA90108C2/uk unknown
- 2005-03-24 FI FIEP21197526.3T patent/FI4008721T3/fi active
- 2005-03-24 SI SI200532297T patent/SI3385267T1/sl unknown
- 2005-03-24 ES ES05742865T patent/ES2371652T3/es active Active
- 2005-03-24 EP EP11167263A patent/EP2377868A1/en not_active Ceased
- 2005-03-24 NZ NZ586824A patent/NZ586824A/en unknown
- 2005-03-24 US US11/088,667 patent/US7714159B2/en active Active
- 2005-03-24 MX MX2014005871A patent/MX367324B/es unknown
- 2005-03-24 CN CN201810192292.1A patent/CN108329337B/zh active Active
- 2005-03-24 NZ NZ550522A patent/NZ550522A/en active IP Right Revival
- 2005-03-24 SI SI200531843T patent/SI2377869T1/sl unknown
- 2005-03-24 RS RS20140186A patent/RS53259B/en unknown
- 2005-03-24 NZ NZ598172A patent/NZ598172A/xx unknown
- 2005-03-24 SG SG200902156-9A patent/SG151322A1/en unknown
- 2005-03-29 PE PE2014001477A patent/PE20142402A1/es not_active Application Discontinuation
- 2005-03-29 PE PE2009001314A patent/PE20110075A1/es active IP Right Grant
- 2005-03-29 NL NL1028639A patent/NL1028639C2/nl not_active IP Right Cessation
- 2005-03-29 TW TW094109818A patent/TWI386212B/zh active
- 2005-03-29 PE PE2005000359A patent/PE20060162A1/es not_active Application Discontinuation
- 2005-03-30 UY UY28830A patent/UY28830A1/es active IP Right Grant
- 2005-03-30 AR ARP050101205A patent/AR049374A1/es active IP Right Grant
-
2006
- 2006-09-21 IL IL178250A patent/IL178250A/en active IP Right Grant
- 2006-09-22 CR CR8653A patent/CR8653A/es unknown
- 2006-10-18 ZA ZA200608689A patent/ZA200608689B/en unknown
- 2006-10-26 NO NO20064893A patent/NO338905B1/no unknown
- 2006-10-27 EC EC2006006960A patent/ECSP066960A/es unknown
-
2007
- 2007-01-08 NL NL1033189A patent/NL1033189C2/nl not_active IP Right Cessation
- 2007-01-08 NL NL1033190A patent/NL1033190C2/nl not_active IP Right Cessation
- 2007-07-19 HK HK07107789.3A patent/HK1100004A1/xx unknown
-
2010
- 2010-02-16 US US12/706,063 patent/US8283467B2/en active Active
- 2010-04-09 CL CL2010000350A patent/CL2010000350A1/es unknown
- 2010-06-01 JP JP2010126333A patent/JP5414625B2/ja active Active
-
2011
- 2011-09-23 DO DO2011000293A patent/DOP2011000293A/es unknown
- 2011-11-14 HR HR20110846T patent/HRP20110846T1/hr unknown
- 2011-11-21 CY CY20111101122T patent/CY1112053T1/el unknown
-
2012
- 2012-04-12 HK HK12103590.4A patent/HK1164320A1/xx unknown
- 2012-05-17 IL IL219853A patent/IL219853A/en active IP Right Grant
- 2012-05-17 IL IL219856A patent/IL219856A/en active IP Right Grant
- 2012-09-14 US US13/615,894 patent/US20130005968A1/en not_active Abandoned
-
2013
- 2013-03-06 JP JP2013043972A patent/JP5894952B2/ja active Active
- 2013-08-07 UY UY34969A patent/UY34969A/es not_active Application Discontinuation
-
2014
- 2014-03-06 US US14/199,265 patent/US20150038706A1/en not_active Abandoned
- 2014-04-08 HR HRP20140339TT patent/HRP20140339T1/hr unknown
- 2014-04-17 CY CY20141100297T patent/CY1115336T1/el unknown
- 2014-05-19 UY UY0001035578A patent/UY35578A/es not_active Application Discontinuation
- 2014-08-11 AR ARP140103013A patent/AR097310A2/es unknown
- 2014-08-11 AR ARP140103012A patent/AR097309A2/es active IP Right Grant
- 2014-08-25 CL CL2014002252A patent/CL2014002252A1/es unknown
-
2015
- 2015-11-30 JP JP2015232705A patent/JP6193960B2/ja active Active
-
2016
- 2016-01-08 US US14/991,363 patent/US9862745B2/en active Active
- 2016-08-24 NO NO20161350A patent/NO344610B1/no unknown
-
2017
- 2017-09-22 US US15/713,005 patent/US10000529B2/en active Active
- 2017-12-05 NO NO20171939A patent/NO343966B1/no unknown
-
2018
- 2018-05-03 HK HK18105728.8A patent/HK1246300A1/zh unknown
- 2018-05-23 US US15/986,972 patent/US20180265546A1/en not_active Abandoned
- 2018-12-13 US US16/218,783 patent/US20190112334A1/en not_active Abandoned
- 2018-12-21 HK HK18116447.5A patent/HK1257298A1/zh unknown
-
2019
- 2019-07-11 US US16/508,706 patent/US20190330270A1/en not_active Abandoned
- 2019-09-04 NO NO20191065A patent/NO20191065A1/no not_active Application Discontinuation
-
2020
- 2020-01-24 US US16/751,374 patent/US20200157143A1/en not_active Abandoned
- 2020-08-13 US US16/992,353 patent/US20200369722A1/en not_active Abandoned
-
2021
- 2021-02-19 US US17/179,508 patent/US20210171574A1/en not_active Abandoned
- 2021-09-02 US US17/465,144 patent/US20210395301A1/en not_active Abandoned
- 2021-11-24 CY CY20211101021T patent/CY1124753T1/el unknown
-
2022
- 2022-03-14 US US17/694,545 patent/US20220204558A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20110075A1 (es) | Sintesis de compuestos de ester borico | |
PE20050158A1 (es) | Compuestos inmunosupresores y composiciones | |
ES2718930T3 (es) | Método de preparación de calcobutrol | |
PE16897A1 (es) | Preparacion de triazoles por adicion organometalica a cetonas e intermedios del mismo | |
NI201100181A (es) | Análogos de isoxazol - 3 (2h ) -ona como agentes terapéuticos | |
PE20120172A1 (es) | Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide | |
PE20071238A1 (es) | Proceso para la preparacion de heterociclos hidroxi substituidos | |
AR071673A1 (es) | Procedimiento para la preparacion de compuestos pirazolicos sustituidos en posiciones 1,3,4 | |
EA201490726A1 (ru) | Фармацевтические соединения для применения в терапии инфекции clostridium difficile | |
RU2011139325A (ru) | Аморфная соль макроциклического ингибитора hcv | |
PA8785001A1 (es) | Compuestos estables en agua, catalizadores y reacciones catalizadas novedosos | |
CU20150051A7 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
PE20120223A1 (es) | Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1) | |
PE20060650A1 (es) | Metodo para preparar irbesartan e intermediarios del mismo | |
MX173525B (es) | Mejoras en un procedimiento para la preparacion de 6-metil-3,4-dihidro-1,2,3-oxatiazin-4-ona-2,2-dioxido por cierre de anillo de un derivado de acetoacetamida | |
PE20110115A1 (es) | Cristal de derivados de espirocetal y procedimiento para la preparacion de derivados de espirocetal | |
AR079575A1 (es) | Procedimiento para la purificacion de pirazoles | |
CR9499A (es) | Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
PA8563601A1 (es) | Acidos-3-(imidazolil)-2- alcoxipropanoicos | |
AR051936A1 (es) | Proceso para la preparacion de pirazoles | |
AR018877A1 (es) | Un procedimiento para la preparacion de derivados de morfolina | |
AR075441A1 (es) | Un proceso para la preparacion de etoricoxib | |
AR059613A1 (es) | Proceso para la preparacion de compuestos de dibenzotiazepina | |
AR035076A1 (es) | Procedimiento y derivados ester utiles para la preparacion de cefalosporinas | |
AR045540A1 (es) | Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |